GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Research & Development

ZBIO (Zenas BioPharma) Research & Development : $139.14 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Zenas BioPharma's Research & Development for the three months ended in Dec. 2024 was $49.16 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $139.14 Mil.


Zenas BioPharma Research & Development Historical Data

The historical data trend for Zenas BioPharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Research & Development Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24
Research & Development
61.69 60.03 139.14

Zenas BioPharma Quarterly Data
Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.42 22.65 33.81 33.53 49.16

Zenas BioPharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $139.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zenas BioPharma  (NAS:ZBIO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Zenas BioPharma Research & Development Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenas BioPharma Business Description

Traded in Other Exchanges
N/A
Address
852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.